Cypher in Japan
This article was originally published in The Gray Sheet
Executive Summary
J&J/Cordis will begin distributing the sirolimus-eluting coronary stent mid-year, co-marketed by Guidant, following Japanese marketing approval, the firm announces March 31. The release will coincide with anticipated reimbursement approval. Japan's Ministry of Health, Labor & Welfare recently lowered reimbursement levels for catheters for cardiac surgery with stents (1"The Gray Sheet" March 1, 2004, p. 27). Approximately 166,000 angioplasties are performed annually in Japan, 70% with stent placement, according to the firm...
You may also be interested in...
Boston Scientific Taxus Japan Launch Delayed Until Second Half Of 2006
Boston Scientific will begin a required Japanese premarket approval trial next year for its Taxus paclitaxel-eluting stent, incorporating a short-term endpoint of major adverse coronary events (MACE)
Japanese Price Revision Cycle Yields Progress Amidst Obstinacy – AdvaMed
U.S. device industry reps expect Japanese "R-zone" price cuts to more closely approximate market conditions than foreign average pricing (FAP) revisions
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”